lenvatinib: new kid on the block
Published 9 years ago • 3.8K plays • Length 6:47Download video MP4
Download video MP3
Similar videos
-
1:28
dr. wirth on the use of lenvatinib in hypertensive patients with thyroid cancer
-
7:03
lenvatinib breakthrough designation, new drug applications for nsclc and sts, and more
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
7:37
lenvatinib as up-front therapy for unresectable hcc
-
3:56
lenvatinib: exploring dose reductions and interruptions
-
4:27
lenvatinib in renal cell carcinoma
-
1:05
dr. brose on unique elements of the lenvatinib trial
-
1:17
dr. marcia brose discusses lenvatinib as a new option in dtc
-
6:56
lenvatinib and lenalidomide approved, new agent promising in myeloma, and more
-
1:59
dr. cohen on lenvatinib in first- or second-line thyroid cancer
-
1:46
dr. bible on impact of lenvatinib on treatment landscape of dtc
-
2:56
dr. finn on role of lenvatinib in hcc treatment paradigm
-
0:48
dr. cabanillas on lenvatinib as first-line therapy for patients with dtc
-
0:59
dr. martins on managing toxicities associated with lenvatinib in dtc
-
5:19
lenvatinib and cabozantinib in renal cell carcinoma
-
0:53
dr. backes on next steps for lenvatinib and weekly paclitaxel in endometrial cancer
-
1:00
lenvatinib in thyroid cancer with and without vegf-targeted therapy
-
3:39
managing patients on lenvatinib/everolimus in mrcc